Haolan Lu

发表论文 34 篇 · 总被引 2184 次 · h-index 16

代表论文

• Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study (2012 · Journal of Clinical Oncology · 被引 1007)
• Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). (2022 · Journal of Clinical Oncology · 被引 194)
• Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors (2021 · Journal of Hematology & Oncology · 被引 150)
• First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors (2021 · The Oncologist · 被引 78)
• ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study. (2022 · Journal of Clinical Oncology · 被引 65)
• OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057 (2017 · Journal of Thoracic Oncology · 被引 52)